Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -8.92% | |
| Wide Bands | Range Expansion | -8.92% | |
| Narrow Range Bar | Range Contraction | -3.38% | |
| Wide Bands | Range Expansion | -3.38% | |
| Shooting Star Candlestick | Bearish | -5.30% | |
| Lizard Bearish | Bearish Day Trade Setup | -5.30% |
| Alert | Time |
|---|---|
| Fell Below 10 DMA | about 11 hours ago |
| Down 5% | about 12 hours ago |
| Down 3% | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Down 2 % | about 15 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.26 |
| 52 Week Low | 1.11 |
| Average Volume | 2,324,601 |
| 200-Day Moving Average | 7.73 |
| 50-Day Moving Average | 6.20 |
| 20-Day Moving Average | 2.05 |
| 10-Day Moving Average | 1.45 |
| Average True Range | 0.39 |
| RSI (14) | 18.70 |
| ADX | 65.68 |
| +DI | 10.95 |
| -DI | 45.02 |
| Chandelier Exit (Long, 3 ATRs) | 7.27 |
| Chandelier Exit (Short, 3 ATRs) | 2.29 |
| Upper Bollinger Bands | 5.84 |
| Lower Bollinger Band | -1.73 |
| Percent B (%b) | 0.42 |
| BandWidth | 368.41 |
| MACD Line | -1.46 |
| MACD Signal Line | -1.68 |
| MACD Histogram | 0.2241 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.97 | ||||
| Resistance 3 (R3) | 2.02 | 1.90 | 1.88 | ||
| Resistance 2 (R2) | 1.90 | 1.76 | 1.87 | 1.85 | |
| Resistance 1 (R1) | 1.66 | 1.67 | 1.60 | 1.61 | 1.82 |
| Pivot Point | 1.54 | 1.54 | 1.51 | 1.51 | 1.54 |
| Support 1 (S1) | 1.30 | 1.40 | 1.24 | 1.25 | 1.04 |
| Support 2 (S2) | 1.18 | 1.31 | 1.15 | 1.01 | |
| Support 3 (S3) | 0.94 | 1.18 | 0.98 | ||
| Support 4 (S4) | 0.89 |
